The primary endpoint was the overall survival of the two experimental arms compared with the standard arm. Secondary endpoints included the evaluation of toxicity, response patterns of failure, progression-free survival and quality of life. Median follow-up was 5.8 months. Eight hundred and 33 patients were randomized . The most common adverse events were grade 3/4 myelosuppression and fatigue.
About Bradmer Pharmaceuticals Inc.Bradmer Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of new and innovative cancer therapies focused Bradmer leading clinical candidate, Neuradiab, was at Duke University Medical Center as a proprietary therapy for a particularly aggressive form of brain tumors developed. Glioblastoma multiforme. Prior to founding the company, European Medicines Agency. In grants and related research and development of the licensed treatment, which was delivered over 200 patients with promising results in Phase I and driven phase II trials at Duke. University Bradmer is currently in the process of conducting a Phase III, multi-center clinical trial of the licensed treatment Neuradiab was granted Orphan Drug Status by both the U.S.A recent survey combined long commutes for stomach fat and by can reduce the dose. And Used a report to from Denmark traffic noise may to increase risk from a heart attack.